Related Experiment Video

Updated: Jun 18, 2026

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway
08:15

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway

Published on: May 10, 2024

Enalapril alters expression of key growth factors in experimental diabetic retinopathy

Hyun Woong Kim1, Jung Lim Kim, Han Kee Lee

  • 1Department of Ophthalmology, College of Medicine, Inje University, Busan Paik Hospital, Busan, South Korea. maekbak@hanmail.net

Current Eye Research
|December 5, 2009
PubMed
Abstract

Insights

Enalapril treatment prevented increased levels of key angiogenic factors, such as VEGF and erythropoietin, in the retinas of diabetic rats. This suggests a potential therapeutic benefit for diabetic retinopathy.

Area of Science:

  • Ophthalmology
  • Diabetology
  • Molecular Biology

Background:

  • Diabetic retinopathy (DR) involves complex angiogenesis driven by multiple factors.
  • Single-factor suppression is insufficient to inhibit DR-related angiogenesis.
  • Understanding the interplay of angiogenic factors is crucial for DR treatment.

Purpose of the Study:

  • To evaluate the expression of multiple angiogenic factors in diabetic rat retinas.
  • To determine the effect of enalapril, an ACE inhibitor, on these factors.
  • To investigate enalapril's potential in managing diabetic retinopathy.

Main Methods:

  • Diabetes induced in Sprague-Dawley rats using streptozotocin.
  • Enalapril administered to a subset of diabetic rats.
  • Retinal expression of VEGF, STAT3/5, erythropoietin, and angiopoietins analyzed via immunohistochemistry, RT-PCR, and Western blotting.

Main Results:

  • Diabetes increased retinal mRNA and protein expression of VEGF, STAT3, erythropoietin receptor, and STAT5.
  • Angiopoietin 2 mRNA and Tie2 mRNA also increased, while angiopoietin 1 mRNA decreased in diabetic rats.
  • Enalapril treatment normalized the expression of these angiogenic factors and their receptors.

Conclusions:

  • Enalapril effectively prevented the upregulation of multiple angiogenic factors in diabetic rat retinas.
  • This study highlights enalapril's potential as a therapeutic agent for diabetic retinopathy.
  • Targeting multiple angiogenic pathways simultaneously may be key in treating DR.

More Related Videos

Retinal Pathophysiological Evaluation in a Rat Model09:11

Retinal Pathophysiological Evaluation in a Rat Model

Published on: May 6, 2022

Related Concept Videos

Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
Diabetic Retinopathy01:27

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...